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        Chemokines are a family of small secreted pro-
teins that activate and attract leukocytes during 
infl  ammation, but also play an important role 
in normal leukocyte traffi   cking, including lym-
phocyte homing. Chemokines exhibit affi   nity 
for seven transmembrane-spanning G protein  –
  coupled signaling receptors and extracellular ma-
trix or cell-bound glycosaminoglycans (GAGs). 
These chemotactic cytokines contain conserved 
cysteine residues in their amino (NH  2  )-terminal 
structure, a characteristic used for classifi  cation 
into CXC, CC, CX  3  C, and C chemokines (  1, 2  ). 
CXCL8 (IL-8), which contains the tripeptide 
Glu-Leu-Arg (ELR) in front of the fi  rst Cys resi-
due, is an infl  ammatory CXC chemokine with 
potent neutrophil chemotactic and angiogenic 
properties (  3  –  6  ). CXCL8 promotes in vivo ac-
tivation and recruitment of neutrophil granulo-
cytes through the chemokine receptors 1 and 2 
(CXCR1 and CXCR2) (  7, 8  ). 
  Chemokine activity is controlled at diff  er-
ent levels, including regulation of chemokine 
and chemokine receptor expression, the pres-
ence of   “  silent  ”   or   “  decoy  ”   chemokine recep-
tors, binding to GAG, and posttranslational 
modification (  9  –  13  ). Leukocytes have been 
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  Biological functions of proteins are infl  uenced by posttranslational modifi  cations such as 
on/off switching by phosphorylation and modulation by glycosylation. Proteolytic processing 
regulates cytokine and chemokine activities. In this study, we report that natural posttrans-
lational citrullination or deimination alters the biological activities of the neutrophil 
chemoattractant and angiogenic cytokine CXCL8/interleukin-8 (IL-8). Citrullination of 
arginine in position 5 was discovered on 14% of natural leukocyte-derived CXCL8(1  –  77), 
generating CXCL8(1  –  77)Cit  5  . Peptidylarginine deiminase (PAD) is known to citrullinate 
structural proteins, and it may initiate autoimmune diseases. PAD effi  ciently and site-
specifi  cally citrullinated CXCL5, CXCL8, CCL17, CCL26, but not IL-1    . In comparison with 
CXCL8(1  –  77), CXCL8(1  –  77)Cit  5   had reduced affi  nity for glycosaminoglycans and induced 
less CXCR2-dependent calcium signaling and extracellular signal-regulated kinase 1/2 
phosphorylation. In contrast to CXCL8(1  –  77), CXCL8(1  –  77)Cit  5   was resistant to thrombin- 
or plasmin-dependent potentiation into CXCL8(6  –  77). Upon intraperitoneal injection, 
CXCL8(6  –  77) was a more potent inducer of neutrophil extravasation compared with 
CXCL8(1  –  77). Despite its retained chemotactic activity in vitro, CXCL8(1  –  77)Cit  5   was 
unable to attract neutrophils to the peritoneum. Finally, in the rabbit cornea angiogenesis 
assay, the equally potent CXCL8(1  –  77) and CXCL8(1  –  77)Cit  5   were less effi  cient angio-
genic molecules than CXCL8(6  –  77). This study shows that PAD citrullinates the 
chemokine CXCL8, and thus may dampen neutrophil extravasation during acute or 
chronic infl  ammation. 
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N-terminal residues, CXCL8(-2  –  77), which is probably the 
result of an alternative cleavage of the signal peptide. Because 
of their instability in the Edman chemistry, the phenyl 
thiohydantoin (PTH)-Cys residues at positions 12 and 14 
of CXCL8(1  –  77) (indicated as X) were not detected after 
Edman degradation and subsequent RP-HPLC. Remarkably, 
in some fractions, the PTH-Arg at position 5 (PTH-Arg  5  ) in 
the sequence of natural CXCL8(1  –  77) was also not identi-
fi  ed (indicated as B), whereas the PTH-Arg  11   present in the 
ELR motif was always detected (sequence AVLPBSAKEL-
RXQXIK). In contrast, recombinant CXCL8(1  –  77) clearly 
showed the consistent presence of this PTH-Arg  5  , whereas 
the PTH-Cys remained undetectable upon sequence analy-
sis. Instead of a PTH-Arg  5   peak, in natural CXCL8(1  –  77) an 
unidentifi  ed compound eluted from the RP-HPLC column 
of the protein sequencer in between PTH-Thr and PTH-
Gly (unpublished data). On classical, noncapillary protein 
sequencers with an HPLC column with a diameter of 2.1 
mm instead of 0.8 mm, the unidentifi  ed residue could not be 
detected because it coeluted with the only partially separated 
PTH-Thr and PTH-Gly peaks. The high background signals 
of PTH-Thr and PTH-Gly and the weak signal for PTH-
Arg on these noncapillary protein sequencers also explain 
why this modifi  cation was not reported before. In addition, 
the experimentally determined average M  r   of 8,917.1  –  8,919 
(Table S1) of natural CXCL8(1  –  77) with the observed mod-
ifi  cation of Arg on position 5 did not signifi  cantly diff  er from 
the theoretical M  r   (8,918.44) of CXCL8(1  –  77). Based on these 
mass spectrometry and Edman degradation data, the diff  er-
ence between natural and recombinant CXCL8 could not 
be explained by a mutation of Arg to one of the other 19 
classical amino acids. Therefore, amino acids generated 
by posttranslational modification of Arg were considered. 
  reported to produce a mixture of proteolytically modifi  ed 
forms of CXCL8, which are derived from secreted intact 
CXCL8, i.e., CXCL8(1  –  77) (  6, 14  ). Limited N-terminal 
truncation by proteases such as thrombin, plasmin, and matrix 
metalloproteinases (MMPs) potentiates the in vitro CXCL8 
activities (  15  –  18  ). However, cleavage in or beyond the ELR 
motif abrogates CXCL8 activity (  19  ). In vivo, no signifi  cant 
diff  erence in neutrophil accumulation or plasma protein exuda-
tion was observed between CXCL8(1  –  77) and CXCL8(6  –  77) 
upon intradermal injection in rabbits or intra  –  air pouch ad-
ministration in mice (  17, 20  ). This apparent contradiction 
between in vitro and in vivo migration experiments may be 
explained by the rapid processing of CXCL8(1  –  77) in vivo, as 
indicated by studies with   Mmp8        /      mice (  17  ). 
  In an attempt to better understand such discrepancies, we 
studied alternatively modifi  ed chemokines and discovered a 
novel natural posttranslational modifi  cation of CXCL8, i.e., 
the conversion of one specifi  c Arg into Cit. The enzyme re-
sponsible for this modifi  cation is peptidylarginine deiminase 
(PAD), for which a genetic association with rheumatoid 
arthritis (RA) has been uncovered (  21  ). In addition, auto-
antibodies to citrullinated proteins are more specifi  c markers 
for RA than IgM rheumatoid factor and are detected in most 
of the patients (  22  ). Diagnostically, such autoantibodies were 
also shown to precede disease onset, implying the possibility 
of an early ontogenic immunological response toward citrul-
linated protein epitopes (  23  ). 
  In this study, natural citrullinated CXCL8 was identifi  ed, 
and the eff  ects of such citrullination were evidenced on the 
in vitro and in vivo activities of CXCL8. In contrast to 
N-terminal processing of CXCL8, the biological consequences 
of citrullination were more pronounced in neutrophil extrava-
sation than in angiogenesis. These fi  ndings demonstrate a novel 
and important additional regulation of chemokine activity in 
infl  ammation. Citrullination aff  ects the migration of neutro-
phils, the most abundant leukocyte type in human blood. 
Moreover, this study indicates that PAD directly modulates 
immune reactions through the modifi  cation of chemokines. 
    RESULTS   
  Identifi  cation of naturally citrullinated isoforms of CXCL8 
  Purifi  ed PBMCs from pooled buff  y coats were induced at 5   ×   
10  6   cells/ml with 10  μ  g/ml polyriboinosinic:polyribocytidylic 
acid and 20 ng/ml IFN-     in RPMI-1640 containing 2% FBS 
for chemokine production ( 24  ). Natural CXCL8 was purifi  ed 
from the conditioned medium by adsorption to controlled 
pore glass, heparin affi   nity, Mono S cation exchange, and C8 
reversed phase HPLC (RP-HPLC), as previously described 
(  6, 25, 26  ). In the column fractions, 11 diff  erent CXCL8 iso-
forms were detected by specifi  c ELISA and identifi  ed by both 
mass spectrometry and amino acid sequencing using Edman 
degradation (  Table I   and Table S1, available at http://www
.jem.org/cgi/content/full/jem.20080305/DC1).   Although 
part of the PBMC-derived CXCL8 was truncated by fi  ve or 
more amino acids, many fractions contained intact CXCL8, 
i.e., CXCL8(1  –  77) and a CXCL8 isoform with two extra 
    Table I.       Identifi  cation of natural CXCL8 by Edman 
degradation and mass spectrometry 
CXCL8 isoform NH  2  -terminal sequence    a    Percentage of total 
amount of CXCL8    b   
    2  1      5       10
CXCL8(-2  –  77) EGAVLPRSAKELRXQX 7.8
CXCL8(-2  –  77)Cit  5 EGAVLPBSAKELRXQX 0.7
CXCL8(1  –  77) AVLPRSAKELRXQX 25.9
CXCL8(1  –  77)Cit  5 AVLPBSAKELRXQX 4.1
CXCL8(2  –  77) VLPRSAKELRXQX 5.5
CXCL8(2  –  77)Cit  5 VLPBSAKELRXQX 0.7
CXCL8(3  –  77) LPRSAKELRXQX 1.1
CXCL8(6  –  77) SAKELRXQX 44.1
CXCL8(8  –  77) KELRXQX 9.0
CXCL8(9  –  77)  ELRXQX 1.2
  a    X stands for an unidentifi  ed residue (on Cys positions) and B stands for citrulline. 
Numbering corresponds to the position of the amino acids in CXCL8(1-77).
  b    The relative amount of the different CXCL8 isoforms was obtained from the yields 
for the different amino acids during Edman degradation on   >  20 RP-HPLC fractions 
from a large batch of leukocytes from pooled blood donations (Table S1, available at 
http://www.jem.org/cgi/content/full/jem.20080305/DC1).JEM VOL. 205, September 1, 2008 
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fraction varied between 0 and 100%, as indicated by Edman 
degradation on all individual fractions. Moreover, citrullina-
tion of this Arg was also detected in the less abundant iso-
forms CXCL8(-2-77) and CXCL8(2  –  77). Arg  11   of natural 
CXCL8(1  –  77) was not modifi  ed in any of these RP-HPLC 
fractions. Overall, 14% of natural CXCL8(1  –  77) and 5.5% 
of total natural CXCL8 from PBMC was citrullinated on 
position 5. The percentage of Cit  5   was calculated from the 
yield of the fi  fth cycle of the Edman chemistry. A detailed 
analysis indicated that CXCL8(1  –  77) and CXCL8(1  –  77)Cit  5   
were only partially separated on heparin affi   nity, cation ex-
change, and C8 RP-HPLC. Compared with CXCL8(1  –  77), 
CXCL8(1  –  77)Cit  5   eluted at slightly lower NaCl concen-
trations from the heparin affi   nity and cation exchange col-
umn and at faintly higher acetonitrile concentrations from 
the C8 RP-HPLC column (Table S1). Because Cit and 
Arg diff  er in one mass unit only, the experimentally deter-
mined mass could not be used as a criterion to predict the 
percentage of citrullination. This also indicates that in body 
fl  uids, citrullination of CXCL8 cannot be detected at pre-
sent by the proteomic approach using ion trap mass spec-
trometry, and that natural proteins need to be purifi  ed to 
homogeneity before identifi  cation of this modifi  cation by 
Edman degradation. 
  Citrullination of CXCL8 by PAD 
  The PAD enzymes catalyze the posttranslational hydroly-
sis of the guanidino group of Arg in proteins, resulting in 
a Cit in the primary structure of these proteins (  Fig. 1 A  ). 
The purity of the commercial rabbit PAD preparation was 
verifi  ed by SDS-PAGE. Two bands were visible after pro-
teins were blotted on PVDF membranes and stained with 
Coomassie blue, one corresponding to BSA and the other to 
PAD, as indicated by Edman degradation (unpublished data). 
Recombinant CXCL8(1  –  77) was incubated with PAD at a 
1:20 or 1:200 enzyme/substrate (E/S) molar ratio. Amino 
acid sequencing revealed that rabbit PAD converted the Arg 
on position 5 (Arg  5  ) into Cit within 30 min at a 1:200 E/S 
molar ratio (  Fig. 1 B  ). As indicated by both Edman degrada-
tion and mass spectrometry analysis, only this N-terminally 
located Arg  5   and no other Arg residues were citrullinated. At a 
1:20 E/S molar ratio, the conversion of Arg  5   occurred more 
rapidly, and only Cit  5   and Arg  11  , but neither Arg  5   nor Cit  11   
were detectable after 5 min (  Fig. 1 B   and not depicted). Al-
though 1 mM dithiothreitol is reported to be added in most 
incubations of proteins with PAD (  27  –  30  ), dithiothreitol was 
not essential for the conversion of Arg  5   in CXCL8(1  –  77) into 
a Cit, indicating that this Arg is highly accessible to the en-
zyme without partial disruption of the secondary structure 
of the protein (unpublished data). Recently, recombinant 
human PAD2 and PAD4 became commercially available. 
At a 1:200 E/S molar ratio and without addition of reducing 
reagents CXCL8(1  –  77) was found to be citrullinated by both 
human PAD2 and PAD4, with a half life for Arg  5   of 12 and 
15 min, respectively (  Fig. 1 B  ). Thus, both human enzymes 
converted CXCL8(1  –  77) into CXCL8(1  –  77)Cit  5   with an 
The only known side chain alteration on Arg that results in a 
minimal change in M  r   (one mass unit) and has been reported 
to occur in some structural proteins is the modifi  cation of 
Arg into Cit (  Fig. 1 A  ).   Therefore,   l-  citrulline was loaded 
on the fi  lter of the protein sequencer, and after one Edman 
degradation cycle the PTH-derivative was detected by RP-
HPLC. PTH-Cit eluted at exactly the same position as the 
unidentifi  ed amino acid on position 5 in natural CXCL8(1  –
  77), i.e., in between PTH-Thr and PTH-Gly (unpublished 
data). This confi  rms that the fi  fth amino acid in part of the 
natural PBMC-derived CXCL8(1  –  77) is posttranslationally 
modifi  ed from Arg into Cit. Because the experimentally de-
termined M  r   of natural CXCL8(1  –  77) did not signifi  cantly 
diff  er from the theoretical M  r   and PTH-Arg  11   was routinely 
detectable, it is expected that other Arg residues present in 
the CXCL8 structure are not or less effi   ciently converted to 
Cit. Simultaneous replacement of all Arg residues by Cit was 
excluded based on the mass spectrometry data on   >  20 frac-
tions containing CXCL8 immunoreactivity from 6 diff  erent 
C8 RP-HPLC columns (Table S1). The relative amount 
of CXCL8(1  –  77) with Cit  5   instead of Arg  5   per RP-HPLC 
    Figure 1.         Modifi  cation of CXCL8 by PAD and production of pure 
citrullinated CXCL8(1  –  77)Cit  5  .   (A) Arginine residues that are incorpo-
rated in protein sequences may be converted into citrulline by PAD. 
(B) Recombinant CXCL8 (5   μ  M) was incubated with rabbit PAD, human PAD2, 
or human PAD4 at an enzyme/substrate (E/S) molar ratio of 1:20 or 1:200 
for different time periods. The presence of Arg (     ) or Cit (     ) at position 5 
was determined by Edman degradation. The percentage of Arg  5   or  Cit 5   in 
the sequence was calculated from the amount of PTH-Arg and PTH-Cit 
that was detected by RP-HPLC after Edman degradation for fi  ve cycles. 
(C) Alternatively, recombinant CXCL8 was incubated for 90 min with PAD 
at an E/S molar ratio of 1:20, purifi  ed by C8 RP-HPLC, and eluted in an 
acetonitrile gradient, and UV absorption was detected at 214 nm. Part of 
the column effl  uent (0.67%) was connected online to an ion trap mass 
spectrometer, and the averaged spectra for the chromatographic peaks 
were deconvoluted to obtain the M  r   of the proteins (top graph).     2088 CXCL8 CITRULLINATION REDUCES NEUTROPHIL CHEMOTAXIS   | Proost et al. 
PAD activity was not detected in either of three commercial 
FBS sources, confi  rming that the leukocytes were the actual 
source of the enzymatic activity (unpublished data). 
  To obtain suffi   cient amounts of pure citrullinated chemo-
kine for bioassays, recombinant CXCL8(1  –  77) was incubated 
with rabbit PAD at a 1:20 E/S molar ratio for 90 min and 
purifi  ed by C8 RP-HPLC. Modifi  ed CXCL8 eluted in one 
major peak from the column with a M  r   of 8,919.0, corre-
sponding to the theoretical M  r   of 8,919.4 (  Fig. 1 C  ). The 
presence of Cit  5   and Arg  11   was confi  rmed by Edman degra-
dation. No CXCL8 that contained a remaining Arg  5   was de-
tected in this preparation (unpublished data). 
  Effect of citrullination on the N-terminal processing 
of CXCL8 by proteases 
  CXCL8(1  –  77) produced by PBMCs is known to be N-ter-
minally truncated into CXCL8(6  –  77) by thrombin and plas-
min (  15, 16  ). Moreover, this truncation has a significant 
impact on the receptor-dependent signaling and in vitro che-
motactic activity of this chemokine. Because the major cleav-
age site in CXCL8 for the serine proteases thrombin and 
plasmin is located between Arg  5   and Ser  6  , the eff  ect of post-
translational modifi  cation of Arg  5   to Cit on the sensitivity of 
CXCL8 to both of these proteases was investigated. As ex-
pected, recombinant intact CXCL8(1  –  77) was almost com-
pletely converted into CXCL8(6  –  77) by thrombin within 
5 min at an E/S ratio of 1:100 as detected by Edman degrada-
tion, ion trap mass spectrometry, and SDS-PAGE analysis 
(  Fig. 2 A   and Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20080305/DC1).   Also, plasmin was able to 
cleave CXCL8 (E/S ratio of 1:100), but plasmin was less pro-
fi  cient than thrombin because only 60% of CXCL8(1  –  77) was 
processed within 0.5 h (  Fig. 2 B   and Fig. S2). In contrast to 
CXCL8(1  –  77), CXCL8(1  –  77)Cit  5   was resistant to thrombin, 
as shown by Edman degradation, and it was also cleaved at a 
effi     ciency comparable to rabbit PAD, also without modi-
fi  cation of Arg  11   in the CXCL8 sequence. To investigate 
whether the citrullination was cytokine specifi  c, recombinant 
IL-1     was incubated with PAD at a 1:20 E/S ratio, desalted, 
and subjected to Edman degradation. The Arg at position 4 in 
the protein sequence of mature biologically active IL-1     has 
been reported to be involved in receptor interactions (  31  ). 
However, no citrullination was observed on either of the 
fi  rst two Arg of IL-1     (positions 4 and 11 in the protein 
sequence of mature IL-1    ; unpublished data). Moreover, on 
ion trap mass spectrometry an average M  r   for PAD-treated 
IL-1     of 17,375 was detected, which is comparable to its 
theoretical average M  r   of 17,377. Although PAD was not able 
to citrullinate IL-1    , incubation of other chemokines with an 
Arg present in their N-terminal region (CXCL5, CCL17, 
and CCL26) was done with rabbit PAD, human PAD2, or 
PAD4. This resulted at the best tested E/S ratios and incu-
bation times in 90  –  100% citrullination of the fi  rst N-termi-
nally located Arg, as indicated by Edman degradation ( Table II ).   
However, CXCL5 and CCL26 were citrullinated more 
slowly compared with CXCL8. Human PAD4, but not hu-
man PAD2, citrullinated the fi  rst N-terminal Arg in CCL17 
with an effi   ciency comparable to that in CXCL8. Moreover, 
the second Arg in CCL17 was also partially citrullinated by 
human PAD4, as well as by PAD2. In analogy with CXCL8, 
no conversion of the second and only other Arg was detected 
in CXCL5, even with 10-fold higher enzyme concentrations. 
In conclusion, citrullination does not appear to be a general 
phenomenon for all cytokines, and in addition occurs pref-
erentially on specifi  c positions such as Arg  5   in the CXCL8 
sequence, which is in accordance with the citrullination of 
natural CXCL8 (vide supra). To exclude that the PAD activity 
in the leukocyte cultures originated from the FBS in the culture 
medium, FBS was tested after standard inactivation for 30 
min at 56  °  C in a recently developed PAD activity assay (  32  ). 
    Table II.        PAD incubation of CXC and CC chemokines 
Chemokine NH  2  -terminal sequence    a   Enzyme E/S    b   Incubation  time    c   Percentage  fi  rst 
Cit    d     
Percentage 
  second Cit    d   
M  r   shift    e   
CXCL5 AGPAAAVL  R  EL  R    CVC  - rabbit PAD 1/20 90 89.8 0 + 1.0
hu PAD2 1/200 120 14.0 0  + 0.4
hu PAD4 1/200 120 35.1 0 + 0.6
CXCL8 AVLP  R  SAKEL  R    CQC  - rabbit PAD 1/20 90 100 0 + 1.1
hu PAD2 1/200 120 88.0 0 ND
hu PAD4 1/200 120 94.5 0 + 1.0
CCL17 A  R  GTNVG  R  E  CC  - hu PAD2 1/200 120 24.8 22.6 + 0.8
hu PAD4 1/200 120 92.1 54.3 + 2.4
CCL26 T  R  GSDISKT  CC  - hu PAD 1/200 120 17.1 ND + 0.2
hu PAD4 1/200 120 17.8 ND + 0.2
hu PAD4 1/40 120 100 ND + 1.3
  a  NH 2  -terminal Arg residues are indicated in bold, cysteine motifs are underlined.
  b  Molar  Enzyme/Substrate  ratio.
  c    Incubation time in minutes.
  d    Percentages of conversion of NH  2 -terminal Arg residues to Cit were determined by Edman degradation.
  e    Shift compared to the theoretical average M  r   of the uncitrullinated chemokine as determined by ion trap mass spectrometry.JEM VOL. 205, September 1, 2008 
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8,095.5; Fig. S2) and upon prolonged incubation also into 
CXCL8(9  –  72) as indicated by mass spectrometry (unpub-
lished data). It can be concluded that Arg  5   citrullination in 
intact CXCL8(1  –  77) protects this chemokine from being 
processed rapidly into the more active infl  ammatory form, 
i.e., CXCL8(6  –  77). 
  Effect of citrullination on CXCR1, CXCR2, and GAG binding 
properties of CXCL8 
  Cells transfected with the two high-affi   nity CXCL8 recep-
tors, CXCR1 and CXCR2, were used to compare the bind-
ing effi   ciency of CXCL8 isoforms. CXCL8(6  –  77) competed 
more effi   ciently than CXCL8(1  –  77) for binding of iodinated 
CXCL8(6  –  77) to CXCR1 (  Fig. 3 A  ).   In addition, CXCL8(1  –
  77)Cit  5   was a more potent competitor for CXCL8 binding 
to CXCR1 compared with CXCL8(1  –  77). In contrast, on cells 
transfected with CXCR2, citrullination of Arg  5   did not aff  ect 
the binding effi   ciency (  Fig. 3 B  ). Removal of the fi  ve N-ter-
minal amino acids resulted in increased CXCL8 binding 
to CXCR2. This indicates that the conversion of the posi-
tively charged Arg into a neutral Cit on the fi  fth position in 
CXCL8(1  –  77) enhances the binding effi   ciency of this chemo-
kine on CXCR1, but not on CXCR2. 
  In addition to binding to seven-transmembrane spanning 
G protein-coupled receptors, CXCL8 interaction with GAG 
is important for in vivo biological activity (  9, 33  ). Because 
chemokine binding to GAG primarily depends on positively 
charged amino acids, and because citrullination induces a reduc-
tion of the chemokine charge, the binding of CXCL8(1  –  77), 
CXCL8(1  –  77)Cit  5  , and CXCL8(6  –  77) to GAG was com-
pared on EpranEx plates treated with heparin (  Fig. 3 C  ) or 
heparan sulfate (  Fig. 3 D  ). Although the fi  rst Arg in the 
CXCL8 sequence is missing in CXCL8(6  –  77), CXCL8(1  –
  77) and CXCL8(6  –  77) had a comparable affi   nity for heparin 
and heparan sulfate. In contrast to truncation, citrullination of 
the fi  rst Arg provoked reduced binding properties on heparin 
and heparan sulfate. Approximately threefold higher concen-
trations of CXCL8(1  –  77)Cit  5   compared with CXCL8(1  –  77) 
and CXCL8(6  –  77) were required to obtain an equal eff  ect in 
the GAG binding assays. 
  Effect of citrullination on receptor signaling and in vitro 
chemotactic properties of CXCL8 
  In the calcium signaling assay on neutrophils, CXCL8(1  –  77) 
and CXCL8(1  –  77)Cit  5   provoked a comparable increase of 
the [Ca  2+  ]  i  . As expected, CXCL8(6  –  77) was fi  vefold more 
potent (  Fig. 4 A  ).   In addition, CXCL8(6  –  77) was 5- to 10-
fold more potent in comparison with intact, unmodifi  ed, and 
citrullinated CXCL8 at desensitizing CXCL8(1  –  77) (  Fig. 4 B  ). 
The signaling capacity of CXCL8(1  –  77)Cit  5   was also eval-
uated on receptor-transfected cells. Despite its higher affi   nity 
for CXCR1, CXCL8(1  –  77)Cit  5   provoked a comparable cal-
cium signal and was equally potent to desensitize CXCR1 
compared with CXCL8(1  –  77) (  Fig. 4, C and D  ). How-
ever, on CXCR2-transfected cells, CXCL8(1  –  77)Cit  5   was 
about twofold less potent in comparison with unmodifi  ed 
much lower rate with plasmin. Indeed, a peptide smaller than 
CXCL8(1  –  77) appeared on the gel upon incubation of 
CXCL8(1  –  77)Cit  5   with plasmin for 1 h or more (  Fig. 2 B  ). 
However, plasmin did not cleave CXCL8(1  –  77)Cit  5   (the-
oretical M  r   8,919.5) into CXCL8(6  –  77) (theoretical M  r   
8,381.8), but rather into CXCL8(9  –  77) (theoretical M  r   
    Figure 2.         Sensitivity of citrullinated CXCL8 to thrombin and plas-
min cleavage.   Recombinant CXCL8(1  –  77) and CXCL8(1  –  77)Cit  5   were 
incubated with thrombin (A) or plasmin (B) for different time periods at 
an enzyme/substrate molar ratio of 1:100. SDS-PAGE was performed un-
der reducing conditions on Tris/tricine gels and proteins were visualized 
by silver staining (  25  ). The bovine trypsin inhibitor (M  r   6,200) is visible as 
the M  r   marker (arrows). Edman degradation and ion trap mass spectrom-
etry analysis were used to calculate the percentage of conversion of 
CXCL8(1 – 77)  or  CXCL8(1 – 77)Cit 5   (black) into CXCL8(6  –  77) (white) or 
CXCL8(9 – 77)  (dashed).   2090 CXCL8 CITRULLINATION REDUCES NEUTROPHIL CHEMOTAXIS   | Proost et al. 
CXCL8(6  –  77) reached its maximal chemotactic activity at a 
concentration of 1 nM, which was 10-fold lower than the opti-
mal concentration of CXCL8(1  –  77) and CXCL8(1  –  77)Cit  5  . 
  Collectively, reduced in vitro CXCR2 signaling and 
GAG binding by citrullination of CXCL8 and protection of 
CXCL8(1  –  77)Cit  5   from proteolytic cleavage into the most 
active CXCL8(6  –  77) would allow us to speculate that in 
vivo neutrophils are less activated to migrate in response to 
CXCL8(1  –  77)Cit  5   than to CXCL8(1 –  77). In addition, CXCL8 
and other CXC chemokines with an ELR motif were reported 
to have angiogenic properties (  5, 34  ). Therefore, we compared 
these CXCL8 forms using in vivo assays for angiogenesis and 
leukocyte infi  ltration. 
  Effect of citrullination on the angiogenic properties 
of CXCL8 after local application in vivo 
  Because the angiogenic activity of the diff  erent CXCL8 forms 
was never compared in vivo, Hydron pellets containing dif-
ferent amounts of CXCL8(1  –  77), CXCL8(1  –  77)Cit  5  , or 
CXCL8(6  –  77) were implanted into corneal micropockets 
in rabbits. Maximal neovascularization occurred between days 
5 and 7 after implantation. At 3 pmol, CXCL8(1  –  77) and 
CXCL8(1  –  77)Cit  5   induced signifi  cant angiogenesis in com-
parison with control pellets, whereas CXCL8(6  –  77) already 
provoked angiogenesis at 0.3 pmol (  Fig. 7 A  ).   At 1 pmol, 
CXCL8(6  –  77) induced maximal angiogenic activity with 
a signifi  cantly higher score compared with CXCL8(1  –  77) 
(P   <   0.05) and CXCL8(1  –  77)Cit  5   (P   <   0.01). No variation in 
CXCL8(1  –  77) in provoking a calcium release and in desensi-
tizing CXCR2 (  Fig. 4, E and F  ). 
  Further investigation on CXCR2 signaling was performed 
by measuring the amount of phosphorylated extracellular sig-
nal-regulated kinase 1/2 (ERK1/2). Truncated CXCL8(6 –  77), 
intact CXCL8(1  –  77), and CXCL8(1  –  77)Cit  5   provoked sig-
nifi  cant phosphorylation of ERK1/2 at a concentration of 10 
nM (  Fig. 5  ).   ERK1/2 phosphorylation induced by CXCL8(1  –
  77)Cit  5   was signifi  cantly lower than CXCL8(6  –  77)  –  induced 
ERK1/2 phosphorylation after 5, 10, and 20 min of stimu-
lation, whereas CXCL8(1  –  77)-induced stimulation only dif-
fered from CXCL8(6  –  77) after 5 min. A signifi  cantly more 
pronounced ERK1/2 phosphorylation with CXCL8(1  –  77) 
compared with citrullinated CXCL8(1  –  77)Cit  5   was also ob-
served after stimulating the cells for 20 min (  Fig. 5  ). Thus, 
both the calcium and ERK1/2 signaling assays on CXCR2-
transfected cells indicate that CXCL8(1  –  77)Cit  5   is weaker than 
authentic CXCL8(1  –  77). It must be concluded that citrullina-
tion of CXCL8 results in a CXCR2-specifi  c reduction of its 
in vitro signaling potency. 
  Authentic CXCL8(1  –  77), CXCL8(1  –  77)Cit  5  , and trun-
cated CXCL8(6  –  77) were compared for their ability to attract 
neutrophils in the Boyden chamber assay. Although the chemo-
tactic response to CXCL8(1  –  77) was moderately higher than 
to CXCL8(1  –  77)Cit  5  , no statistically signifi  cant diff  erence 
in activity was detected (  Fig. 6  ).   In contrast, CXCL8(6  –  77) 
provoked a signifi  cantly higher chemotactic response in com-
parison with CXCL8(1  –  77)Cit  5   and CXCL8(1  –  77). Truncated 
    Figure 3.         Effect of citrullination on the receptor and GAG binding properties of CXCL8.   Increasing concentrations of unlabeled chemokine were 
added together with   125  I-CXCL8 to HEK293 cells transfected with CXCR1 (A) or CXCR2 (B). Results represent the mean percentage (  ±   the SEM) of remain-
ing specifi  c   125  I-CXCL8 binding (  n   = 4). Alternatively, GAG binding was evaluated by immobilizing low molecular weight heparin (C) or heparan sulfate (D) 
on EpranEx plates. CXCL8 isoforms bound to GAG were detected with biotinylated anti-CXCL8 antibodies and peroxidase-conjugated streptavidin. The 
optical densities obtained without addition of CXCL8 and with addition of 300 nM CXCL8(1  –  77) were set to 0 and 100%, respectively. Results represent 
the mean percentage of specifi  c chemokine binding (six or more independent experiments)   ±   the SEM to heparin or heparan sulfate for human CXCL8(1  –
 77)  (    ),  CXCL8(6 – 77)  (   ),  or  CXCL8(1 – 77)Cit 5   (    ). Statistical differences between CXCL8(1  –  77) and CXCL8(1  –  77)Cit  5   or CXCL8(6  –  77) were detected using 
the Mann-Whitney   U   test (*, P   <   0.05; **, P   <   0.01; ***, P   <   0.001).     JEM VOL. 205, September 1, 2008 
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phils at 2 h after injection, confi  rming the observed in vitro 
diff  erence in chemotactic potency between these two CXCL8 
forms (  Fig. 7, B and C  ). In contrast to authentic CXCL8(1  –
  77), which is active at 30 pmol, up to 100 pmol of CXCL8(1  –
  77)Cit  5   was still unable to induce an increase of the total 
number or the percentage of peritoneal neutrophils. Thus, 
despite the lack of an eff  ect of citrullination on the in vitro 
chemotactic activity of CXCL8, citrullination of CXCL8 
signifi  cantly reduced neutrophil extravasation to the perito-
neal cavity. These fi  ndings are in agreement with reduced 
GAG binding, CXCR2 signaling, and resistance to N-terminal 
proteolytic potentiation. The inhibitory eff  ect of citrullination 
neovascularization was observed between CXCL8(1  –  77) and 
CXCL8(1  –  77)Cit  5   despite the latter being weaker in CXCR2 
signaling and GAG binding (  Fig. 3, Fig. 4, and Fig. 7 A  ). 
However, the enhanced CXCR1 binding of CXCL8(1  –  77)
Cit  5   may counteract this imbalance. 
  Effect of CXCL8 citrullination on neutrophil extravasation 
  To study the eff  ect of CXCL8 citrullination on leukocyte 
emigration from the blood circulation into tissues, CXCL8(1  –
  77), CXCL8(6  –  77), and CXCL8(1  –  77)Cit  5   were injected 
i.p. in mice. Mice were killed after 2 h (  Fig. 7, B and C  ) or 
4 h (not depicted) and leukocyte accumulation in the perito-
neal cavity was evaluated. None of the three CXCL8 iso-
forms induced an increase in the number of peritoneal 
lymphocytes or macrophages (unpublished data). In this 
model, maximal accumulation of neutrophils in the perito-
neum was obtained at 2 h after injection. CXCL8(6  –  77) was 
threefold more potent than CXCL8(1  –  77) to attract neutro-
    Figure 4.         Calcium signaling capacity and receptor desensitization 
of citrullinated CXCL8 in neutrophils and HEK293 cells transfected 
with CXCR1 or CXCR2.   The increase in intracellular calcium concentra-
tion ([Ca  2+ ] i  ) in neutrophils and HEK293 cells transfected with CXCR1 or 
CXCR2 was measured using the ratiometric dye Fura-2. The cells were 
stimulated with CXCL8(1  –  77) (     ), CXCL8(6  –  77) (    ),  or  CXCL8(1 – 77)Cit 5   (   ). 
Values represent the mean (  ±   the SEM) increase of [Ca  2+ ] i   (nM) with a 
detection limit at 20 nM (dotted line; neutrophils,   n   = 5 [A]; HEK-CXCR1, 
  n   = 3 [C]; HEK-CXCR2,   n   = 5 [E]). Desensitization experiments were per-
formed by rechallenging the cells with 5 nM of CXCL8(1  –  77) 100 s after 
the fi  rst stimulus. Results (mean   ±   the SEM) represent the percentage of 
inhibition of the second agonist by the fi  rst stimulus in comparison with 
buffer as the fi  rst stimulus (neutrophils,   n   = 5 [B]; HEK-CXCR1,   n   = 3 [D]; 
HEK-CXCR2,   n   = 5 [F]). Signifi  cant differences were calculated using the 
Mann-Whitney   U   test on paired values ( *, P   <   0.05; **, P   <   0.01 for com-
parison  between  CXCL8[1 – 77]  and  CXCL8[1 – 77]Cit 5 ) .      
    Figure 5.         Phosphorylation of ERK1/2 by CXCL8 forms.  The  amount 
of phosphorylated ERK1/2 (pg phospho ERK1/2 per mg total protein) was 
measured by a specifi  c ELISA after stimulation of serum-starved CXCR2-
transfected HEK293 cells for 5, 10, or 20 min with medium (co), 10 nM of 
CXCL8(1 – 77),  CXCL8(6 – 77),  or  CXCL8(1 – 77)Cit 5  . Results represent the 
percentage ERK1/2 phosphorylation (  ±   the SEM) compared with medium-
treated control cells (three to four independent experiments). Statistical 
analysis was performed using the Mann-Whitney   U   test on paired values 
(*, P   <   0.05 for comparison with CXCL8[1  –  77]).     
    Figure 6.         In vitro neutrophil chemotactic activity of citrullinated 
CXCL8.   The chemotactic activity of CXCL8(1  –  77), CXCL8(1  –  77)Cit  5 ,  and 
CXCL8(6  –  77) for neutrophils was measured using a Boyden microchamber 
(four to six independent experiments). The chemotactic index (  ±   the SEM) 
was calculated by dividing the number of migrated cells toward test sam-
ples by the number of spontaneously migrated cells toward buffer. Statis-
tical analysis was performed using the Mann-Whitney   U   test on paired 
values (*, P   <   0.05; **, P   <   0.01; ***, P   <   0.001 for comparison with the 
corresponding  concentration  of  CXCL8[1 – 77]).   2092 CXCL8 CITRULLINATION REDUCES NEUTROPHIL CHEMOTAXIS   | Proost et al. 
of CXCL8 on neutrophil recruitment in vivo was even more 
profound than the enhancing eff  ect of N-terminal trunca-
tion, yielding a diff   erence of at least 10-fold between 
CXCL8(1  –  77) and CXCL8(1  –  77)Cit  5  . 
    DISCUSSION   
  During the past decade, posttranslational modifi  cation of che-
mokines has been reported to aff  ect their in vitro and in vivo 
activities (  11  ). Primarily N-terminal processing alters the re-
ceptor affi   nity and specifi  c biological activity of chemokines. 
This includes minimal modifi  cation of an N-terminal Gln to 
pyroglutamic acid in the three monocyte chemotactic proteins, 
CCL2/MCP-1, CCL8/MCP-2, and CCL7/MCP-3, for 
which this pyroglutamic acid is essential for full biological ac-
tivity (  26, 35  ). Proteolytic processing of the N terminus of che-
mokines results in enhanced or reduced activity depending on 
the chemokine, protease, and degree of processing involved. In 
addition to the numerous naturally occurring forms of N-ter-
minally truncated chemokines, a limited number of C-termi-
nally processed chemokines have been identifi  ed (CCL2, 
CXCL7, and CXCL10) (  36  –  38  ). Some chemokines, e.g., 
CCL2 and CCL11, may also be glycosylated (  39, 40  ). Despite 
the signifi  cant increase in M  r  , glycosylation only moderately 
(twofold) infl  uences the in vitro activities of natural human 
CCL2 (  38  ). N-terminal truncation of CXCL8 by thrombin, 
plasmin, MMP-8, or MMP-9 by fi  ve to eight amino acids has 
been reported to signifi  cantly increase its in vitro receptor sig-
naling and chemotactic activity (  15  –  18  ). C-terminal truncation 
of CXCL8 resulted in reduced heparin-binding properties (  33  ). 
In addition to N-terminal proteolytic processing, this study re-
veals a novel biologically relevant enzymatic modifi  cation of 
Arg into citrulline (Cit) at position fi  ve of natural leukocyte-
derived CXCL8. 
  The presence or absence of a Cit in natural CXCL8 was 
indicated by a combination of mass spectrometry and cap-
illary protein sequencing (  Table I  ). Purifi  cation of CXCL8 
immunoreactivity from PBMC-conditioned medium to 
homogeneity by heparin affi   nity, cation exchange, and RP-
HPLC revealed that 14% of CXCL8(1  –  77) and 5.5% of total 
CXCL8 was posttranslationally modifi   ed on Arg  5  . How-
ever, it can be speculated that the amount of citrullinated 
CXCL8 produced by fi  broblasts or endothelial cells in the 
synovial cavity of RA patients is substantially higher because 
CXCL8 produced by these cell types is predominantly not 
CXCL8(6  –  77) lacking Arg  5  , but intact CXCL8 (  6, 14, 41  –  45  ). 
Because citrullination alters the M  r   of proteins by only one 
mass unit, this posttranslational modifi  cation could not be 
detected by mass spectrometry alone and had to be indicated 
by capillary Edman degradation on purifi  ed proteins. At pre-
sent, the requirement for extensively purifi  ed proteins is a 
signifi  cant handicap in the analysis of natural CXCL8 in com-
plex samples such as body fl  uids of patients in which CXCL8 
is present in only nanogram/milliliter concentrations within 
mixtures of milligram/milliliter contaminating proteins. 
Because all miniaturized protein purifi  cation techniques to 
analyze small volumes of complex samples that have been 
    Figure 7.         Effect of citrullination on CXCL8-induced angiogenesis 
and neutrophil extravasation in vivo.   (A)   Neovascularization  induced 
by  CXCL8(1 – 77),  CXCL8(1 – 77)Cit 5  , and CXCL8(6  –  77) was tested in a rabbit 
corneal micropocket. Angiogenesis was scored daily (score 0  –  4) from days 
4 to 8. The angiogenic index was calculated by dividing the maximal neo-
vascularization scores (occurring between days 5 and 7) by the spontane-
ous angiogenesis score obtained with PBS (co). (B and C) Induction of 
neutrophil infi  ltration was measured in NMRI mice by i.p. injection of 200   μ  l 
vehicle (0.9% NaCl = co), CXCL8(1  –  77), CXCL8(6  –  77), or CXCL8(1  –  77)
Cit  5  . After 2 h, mice were killed and the peritoneal cavity was washed. The 
total amount of leukocytes per microliter of peritoneal lavage solution 
was determined, and cytospins were stained with Hemacolor solutions to 
determine the percentage of neutrophils. The fi  gures denote the median 
(squares), the 25  –  75% range (boxes), the nonoutlier range (whiskers), and 
the extreme values (     ) acquired from 5  –  9 replicates (eyes; A) or 12  –  21 
mice (B and C) per CXCL8 dose. Statistical analysis was performed using 
the Mann-Whitney   U   test  ( § ,  P   <   0.05;   §  § ,  P   <   0.01;   §  §  § ,  P   <   0.001  for 
comparison with vehicle alone; *, P   <   0.05; **, P   <   0.01 for comparison 
with  CXCL8[6 – 77]).   JEM VOL. 205, September 1, 2008 
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could have consequences for angiogenic and infl  ammatory 
processes (  64  ). Suzuki et al. reported that in Japanese popula-
tion cohorts, SNPs in the human   PADI4   gene were strongly 
associated with susceptibility to RA, although this association 
was not found in studies that were conducted in the UK and 
France (  21, 65, 66  ). Deimination of Arg was also reported in 
association with MS (  62, 67  ). PAD2-dependent citrullination 
of MBP was suggested to play an important role in MS pa-
tients (  68  ). Citrullination of MBP is increased in MS patients 
(  69  ) and exposes immunodominant epitopes (  70  ); it renders 
MBP more susceptible to cleavage with cathepsin D (  29  ), 
and may therefore initiate loss of myelin stability. 
  This study reports natural and site-specific citrullina-
tion of a cytokine, i.e., the chemokine CXCL8 by rabbit 
PAD, human PAD2, and human PAD4. Moreover, another 
CXCR2 ligand, CXCL5, was also site-specifi  cally citrulli-
nated by these enzymes, but less rapidly than CXCL8. Two 
CC chemokines, CCL17 and CCL26, were also citrullinated 
by human PAD2 and PAD4 with diff  erent  eff  ectiveness. 
Citrullination of CCL17 with human PAD2 or PAD4 was 
slower compared with that of CXCL8. In contrast to the 
other chemokines tested, the fi  rst and the second N-termi-
nally located Arg of CCL17 were both modifi  ed. In addition, 
CCL17 appeared to be the only substrate on which PAD4 
was more effi   cient compared with PAD2 in posttranslation-
ally modifying the Arg residues. In contrast to most other 
previously identifi  ed PAD substrates, which were primar-
ily abundant structural proteins, chemokines directly aff  ect 
immune functions and ELR  +   CXC chemokines such as 
CXCL8 promote angiogenesis. Therefore, PAD-activity may 
not only interfere with autoimmunity in the long term 
through the stimulation of the production of anti-citrulline 
antibodies, but PAD may also directly alter immunological 
processes. Because cytokines such as IL-1     and TNF-     are 
important players in autoimmune diseases such as RA, the 
possible interaction of PAD with IL-1     was also investigated 
(  71  –  73  ). The failure of PAD to convert Arg to Cit in IL-1     
(with N-terminal arginines at positions comparable to those 
of CXCL8) shows that citrullination is not only a site-spe-
cifi  c but also a cytokine-specifi  c phenomenon. The rapid 
in vitro citrullination of CXCL8 and other chemokines by 
PAD without addition of reducing agents and the isolation 
of natural citrullinated CXCL8(1  –  77)Cit  5   from PBMCs both 
underscore the importance of this enzyme in chemokine bi-
ology. Actually, most of the in vitro incubations with PAD 
on other reported substrates were performed in the presence 
of reducing agents. These conditions may render Arg resi-
dues, which are protected by the three-dimensional structure 
of the protein, accessible for enzymatic processing (  27  –  30  ). 
In vitro, CXCL8(1  –  77)Cit  5   and uncitrullinated CXCL8(1  –  77) 
were equally potent in neutrophil chemotaxis assays. The sig-
nificantly enhanced CXCR1 binding, and the reduced 
CXCR2-dependent signaling effi   ciency, as detected on re-
ceptor-transfected cells, could account for this unaltered in 
vitro chemotactic activity (  Figs. 3  –  6  ). However, in contrast to 
CXCL8(1  –  77), CXCL8(1 –  77)Cit  5   was resistant to cleavage 
developed during the last decade depend on identifi  cation of 
proteins by mass spectrometry, the detection of citrullinated 
CXCL8 in patient samples is hampered. Indeed, N-termi-
nally truncated chemokine forms that diff  er in   >  100 mass 
units have been identifi  ed in body fl  uids of cancer patients 
by mass spectrometry (  46  ). Furthermore, a good correlation 
with the in vitro occurrence of these truncated chemokine 
forms was observed. 
  Incubation of CXCL8 with rabbit PAD, human PAD2, 
and human PAD4 rapidly converted recombinant CXCL8(1 –
  77) into CXCL8(1  –  77)Cit  5  , indicating that in all likelihood 
this enzyme is responsible for the observed posttranslational 
modifi  cation of natural CXCL8 (  Fig. 1  ). Deimination of an 
Arg to Cit, which results in the loss of one positive charge 
and in only a single mass unit increase of the M  r  , is a known 
natural posttranslational modifi  cation. Citrullination has pre-
viously been observed for proteins such as vimentin, keratin, 
fi  laggrin,     -enolase, myelin basic protein (MBP), the prote-
ase inhibitor anti-thrombin, and some nuclear proteins, e.g., 
histones, nucleophosmin, and p300, but was never reported 
before for cytokines or chemokines (  28, 30, 47  –  53  ). To date, 
fi  ve human genes have been described that code for PAD, 
i.e.,   PADI1, 2, 3, 4   and   6   (  54  –  57  ). PAD is diff  erentially ex-
pressed in various organs depending on the isotype (  58  ). Most 
PAD protein is present in the cytoplasm, although during in-
fl  ammation PAD enzymes have been detected extracellularly 
(  41  ) and the extracellular calcium concentration is suffi   ciently 
high for PAD activity and citrullination of extracellular pro-
teins such as fi  brin (  59  ). PAD1 is primarily expressed in the 
uterus, and both PAD1 and PAD3 are found in the epider-
mis, where they citrullinate structural proteins such as kera-
tin, fi  laggrin, and trichohyalin (  58  ). Both PAD1 and PAD3 
are absent in PBMCs (  41, 60  ). PAD2 is known to process 
vimentin and MBP, and is widely expressed and highly abun-
dant in skeletal muscle, brain, spleens, and secretory glands. 
In contrast to PAD1, PAD3, and PAD6 proteins, both PAD2 
and PAD4 have been detected in hematopoietic cells. PAD4 
expression is mainly restricted to leukocytes and in contrast 
to other PADs, PAD4 has been detected in the nucleus. The 
most recently identifi  ed PAD, PAD6, is found in male and 
female germ cells and is a crucial enzyme in fertility. The en-
zyme is essential for normal development of an embryo be-
yond the two-cell stage (  54, 61  ). 
  Modifi  cation of Arg into Cit has been linked to auto-
immune diseases such as RA and multiple sclerosis (MS) (  27, 
62, 63  ). Citrullination of proteins is even suggested to initiate 
the generation of autoimmune reactions. In serum of RA 
patients, citrullinated fi  brin appeared to be the major target 
of the anti-citrulline peptide antibodies. A synthetic cyclic 
citrullinated peptide (CCP) construct is used nowadays as a 
diagnostic tool to distinguish RA from other arthritic disor-
ders and possesses a highly predictive value for future devel-
opment of RA in healthy individuals and patients with 
undiff  erentiated arthritis (  22, 23  ). In addition to citrullination 
of structural proteins, increased levels of citrullinated anti-
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on structural proteins that cause autoimmune diseases but may 
initially function as an enzyme that dampens infl  ammation by 
reducing the local infl  ux of neutrophils. 
    MATERIALS AND METHODS   
  Reagents and cells.     Recombinant human chemokines and cytokines were 
obtained from PeproTech. Human thrombin (2,532 NIH U/mg) and plas-
min (3  –  6 U/mg), PAD purifi  ed from rabbit skeletal muscle (200 U/mg), 
and double-stranded RNA polyriboinosinic:polyribocytidylic acid were 
purchased from Sigma-Aldrich. LPS from   Escherichia coli   0111:B4 was ob-
tained from Difco Laboratories. Recombinant human PAD2 and PAD4 
and the antibody-based assay for PAD activity (ABAP kit) were purchased 
from MediQuest Research. Endotoxin concentrations were evaluated 
with the Limulus amoebocyte lysate test (Cambrex). Human embryonic 
kidney (HEK)293 cells transfected with CXCR1 or CXCR2 were a gift 
of J.M. Wang (National Cancer Institute, Frederick, MD) (  75  ). PBMCs 
and granulocytes were purifi  ed from fresh human buff  y coats (  25  ). Granulo-
cytes from individual donors were used for chemotaxis and calcium signal-
ing experiments. 
  Purifi  cation and identifi  cation of natural chemokines.     Natural human 
CXCL8 was purifi  ed using a four-step purifi  cation procedure (  25  ). Proteins 
were eluted from the fi  nal reversed phase (RP-)HPLC column (2.1   ×   220 mm 
Brownlee C-8 Aquapore RP-300 column; PerkinElmer) with an aceto-
nitrile gradient in 0.1% TFA, detected at 214 nm, and 1/150 part of the 
column fl  ow was split online to an electrospray ion trap mass spectrometer 
(Esquire LC). Averaged profi  le spectra were calculated over the CXCL8 
containing fractions as measured by ELISA (  76  ). The N-terminal sequence 
of proteins was determined on a 491 Procise cLC protein sequencer (Ap-
plied Biosystems). 
  In vitro citrullination and truncation of CXCL8.     Proteins were incu-
bated with PAD in 40 mM Tris-HCl, pH 7.4, and 2 mM CaCl  2   at 37  °  C. 
Deimination was stopped with 0.1% TFA and samples were desalted on C4 
or C18 ZipTip (Millipore) before mass spectrometry or spotted on PVDF 
membranes (ProSorb; Applied Biosystems) before Edman degradation. For 
use in bioassays, citrullinated proteins were purifi  ed on a C8 Aquapore RP-
300 HPLC column (1   ×   50 mm). 
  Alternatively, CXCL8 was incubated with thrombin in PBS containing 
1 mM CaCl  2   or with plasmin in 50 mM Tris, pH 7.4, at 37  °  C. Proteolysis 
was stopped by adding 0.1% TFA before Edman degradation on PVDF 
membranes or with 50 mM Tris-HCl, pH 6.8, 4% SDS, 12% glycerol, 2% 
2-mercaptoethanol, and 0.019% Brilliant blue G, followed by heating for 
5 min at 95  °  C before SDS-PAGE (  25  ). 
  In vitro chemotaxis and signaling assays.     Neutrophil chemotaxis was 
performed in Boyden microchambers (Neuro Probe) and the chemotactic 
index was calculated (  25  ). Changes in intracellular calcium concentration 
([Ca  2+  ]  i  ) were measured with the ratiometric fl  uorescent dye Fura-2/AM 
(Invitrogen) (  77  ). Phosphorylation of ERK1/2 was determined using a spe-
cifi  c ELISA for phospho-ERK1 and phospho-ERK2 (R  &  D Systems) (  76  ). 
  Receptor and GAG binding assays.    Competition for   125  I-labeled CXCL8 
binding was measured on HEK293 cells transfected with CXCR1 or 
CXCR2 in binding buff  er (50 mM Hepes, pH 7.2, containing 1 mM CaCl  2  , 
5 mM MgCl  2  , and 0.1% [wt/vol] bovine serum albumin). In brief, 2   ×   10  6   
cells were incubated for 2 h at 4  °  C with   125  I-CXCL8 (PerkinElmer) and un-
labeled chemokine. Cells were centrifuged and washed three times with 2 ml 
of binding buff  er supplemented with 0.5 M NaCl and the radioactivity was 
measured in a gamma counter (Hidex; Finland). 
  GAG binding was evaluated by immobilizing low molecular weight 
heparin or heparan sulfate (Sigma-Aldrich) on EpranEx plates (Plasso Tech-
nology, Ltd.) (  78  ). In brief, 25   μ  g/ml of GAG diluted in PBS was coated 
overnight at room temperature on 96-well plates. Plates were washed three 
by thrombin into CXCL8(6  –  77) (  Fig. 2  ). Conversion of 
CXCL8(1  –  77) into CXCL8(6  –  77) by thrombin rapidly 
occurs in infl  amed tissues, and this proteolytic N-terminal 
truncation results in enhanced in vitro activity of CXCL8 
(  15  ). Depending on the cells and enzymes that are pre-
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